Thousand Oaks-based Amgen and fellow biopharmaceuticals firm Merck said this morning that they are in an agreement to create a combination treatment for advanced melanoma. The two said they are looking to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, to treat mid to late-stage melanoma. Financial details of the collaboration were not announced by the companies.
Top NewsWednesday, February 5, 2014
Amgen, Merck In Collaboration Over Melanoma Treatments